HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder gel could help patients avoid bladder removal surgery
Disease control Not yet recruitingThis study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if th…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Bladder cancer patients may get new hope from virus treatment
Disease control Not yet recruitingThis phase 2 trial tests a virus-based drug given directly into the bladder for people with high-risk non-muscle invasive bladder cancer. The virus is designed to attack cancer cells and trigger the immune system. About 18 participants will receive increasing doses to find the sa…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Bladder cancer trial pits radiotherapy against standard immunotherapy
Disease control Not yet recruitingThis phase 3 trial compares radiotherapy with a radiosensitiser to the standard BCG immunotherapy for high-risk non-muscle invasive bladder cancer. About 328 patients will be randomly assigned to one of the two treatments after tumor removal. The goal is to see which approach bet…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for tough bladder cancer: immune drug plus chemo combo enters trial
Disease control Not yet recruitingThis study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC